Problems in clinical use of recombinant proteins;Problemer ved klinisk brug af rekombinante proteiner

Ugeskrift for Laeger

Volumn 165, Issue 48, 2003, Pages 4625-

  Bendtzen, Klaus ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; RECOMBINANT PROTEIN;

B LYMPHOCYTE; DOSE RESPONSE; EDITORIAL; IMMUNITY; IMMUNOGENICITY; IMMUNOLOGY; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; SPONDYLOARTHROPATHY; T LYMPHOCYTE;

ANTIBODY FORMATION; HUMANS; RECOMBINANT FUSION PROTEINS;

EID: 1642472745     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (3)

1. Bendtzen K. Immunogenicitet af biologiske lægemidler. Ugeskr Læger 2003; 165:4629-32.
2. Ross C, Clemmesen KM, Svenson M et al. Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurology 2000;48:706-12.
3. Dahlin J, Sørensen SF. Erfaringer med infliximab til behandling af aktiv reumatoid artrit og spondylartropati. Ugeskr Læger 2003;165:4646-9.